Alliancebernstein L.P. Vertex Pharmaceuticals Inc Transaction History

Alliancebernstein L.P.

$275 Billion
Q1 2024

A detailed history of Alliancebernstein L.P. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Alliancebernstein L.P. holds 7,097,281 shares of VRTX stock, worth $3.23 Billion. This represents 1.08% of its overall portfolio holdings.

Number of Shares

7,097,281

Previous 7,039,738 0.82%

Holding current value

$3.23 Billion

Previous $2.86 Billion 3.57%

% of portfolio

1.08%

Previous 1.12%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$407.69 - $446.08 $23.5 Million - $25.7 Million	57,543 Added 0.82%	7,097,281 $2.97 Billion
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $167 Million - $200 Million	-486,718 Reduced 6.47%	7,039,738 $2.86 Billion
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $2.9 Million - $3.11 Million	-8,578 Reduced 0.11%	7,526,456 $2.62 Billion
Q2 2023 Aug 15, 2023	SELL	$314.42 - $351.91 $264 Million - $295 Million	-838,239 Reduced 10.01%	7,535,034 $2.65 Billion
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $197 Million - $225 Million	-696,307 Reduced 7.68%	8,373,273 $2.64 Billion

Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $21.7 Million - $24.4 Million	-75,936 Reduced 0.83%	9,069,580 $2.62 Billion
Q3 2022 Nov 15, 2022	SELL	$273.83 - $305.53 $42.4 Million - $47.3 Million	-154,714 Reduced 1.66%	9,145,516 $2.65 Billion
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $295 Million - $367 Million	-1,254,811 Reduced 11.89%	9,300,230 $2.62 Billion
Q1 2022 May 13, 2022	BUY	$221.42 - $260.97 $24.6 Million - $29 Million	111,270 Added 1.07%	10,555,041 $2.75 Billion
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $243 Million - $307 Million	1,374,923 Added 15.16%	10,443,771 $2.29 Billion
Q3 2021 Nov 10, 2021	BUY	$181.39 - $202.99 $488 Million - $546 Million	2,690,416 Added 42.18%	9,068,848 $1.64 Billion
Q2 2021 Jul 30, 2021	SELL	$187.49 - $221.1 $278 Million - $327 Million	-1,480,175 Reduced 18.84%	6,378,432 $1.29 Billion
Q1 2021 May 06, 2021	SELL	$207.02 - $241.31 $17.2 Million - $20.1 Million	-83,154 Reduced 1.05%	7,858,607 $1.69 Billion
Q4 2020 Feb 08, 2021	BUY	$207.01 - $276.09 $278 Million - $371 Million	1,342,210 Added 20.34%	7,941,761 $1.88 Billion
Q3 2020 Nov 12, 2020	BUY	$255.65 - $303.1 $208 Million - $247 Million	813,580 Added 14.06%	6,599,551 $1.8 Billion
Q2 2020 Aug 13, 2020	SELL	$225.48 - $295.8 $92 Million - $121 Million	-407,880 Reduced 6.59%	5,785,971 $1.68 Billion
Q1 2020 May 14, 2020	SELL	$199.77 - $247.81 $33.5 Million - $41.6 Million	-167,782 Reduced 2.64%	6,193,851 $1.47 Billion
Q4 2019 Feb 18, 2020	BUY	$166.71 - $223.91 $96.8 Million - $130 Million	580,418 Added 10.04%	6,361,633 $1.39 Billion
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $114 Million - $128 Million	686,812 Added 13.48%	5,781,215 $979 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $293 Million - $338 Million	1,777,171 Added 53.57%	5,094,403 $934 Million
Q1 2019 May 14, 2019	BUY	$163.73 - $194.7 $63.3 Million - $75.3 Million	386,502 Added 13.19%	3,317,232 $610 Million
Q4 2018 Feb 13, 2019	BUY	$151.91 - $192.21 $364 Million - $460 Million	2,394,289 Added 446.33%	2,930,730 $486 Million
Q3 2018 Nov 08, 2018	BUY	$167.73 - $192.74 $6.77 Million - $7.77 Million	40,336 Added 8.13%	536,441 $103 Million
Q2 2018 Aug 13, 2018	BUY	$145.72 - $169.96 $4.35 Million - $5.07 Million	29,847 Added 6.4%	496,105 $84.3 Million
Q1 2018 May 14, 2018	SELL	$151.6 - $177.13 $761,032 - $889,192	-5,020 Reduced 1.07%	466,258 $76 Million
Q4 2017 Feb 13, 2018	SELL	$137.28 - $155.55 $963,156 - $1.09 Million	-7,016 Reduced 1.47%	471,278 $70.6 Million
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $70.8 Million - $77.6 Million	478,294	478,294 $72.7 Million

Others Institutions Holding VRTX

# of Institutions

1,623

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $117B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Vertex Pharmaceuticals Inc Transaction History